In June 2022 we reported that favourable results from a trial of a new cancer drug, Enhertu (trastuzumab deruxtecan), had been presented at this year’s meeting of the American Society of Clinical Oncology and had been published in the “New England Journal of Medicine”. Enhertu is a specifically engineered HER-2-directed antibody drug conjugate which has…
Dr Coffelt and his team at the Beatson Institute for Cancer Research in Glasgow in another project funded by Secondary1st’s fundraisers and donors are working to understand why existing immunotherapies are less effective in treating breast cancer than other cancer types. They recently published a report on a significant discovery that breast cancer immunotherapy could…
At the University of Bradford in one of the projects funded by the wonderful donors and fundraisers of Secondary1st Professor Pors and his PhD student Enrica are continuing their work to improve duocarmycins, a very effective but highly toxic chemotherapy, so that they can be used to treat breast cancer. In the second year of…